CALGARY, Alberta, May 13, 2025 (GLOBE NEWSWIRE) -- Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) announces first quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights $91 million in revenue;$68 million in funds from operations ($0.42/share) (1)(3);$44 million in dividends paid ($0.27/share)(2);10,635 bbls/d of total liquids production, an 8% increase from previous quarter driven by continued execution of our U.S. expansion strategy and heavy oil growth in Canada;1 ...

Sitio Royalties (STR) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Ladies and gentlemen, thank you for attending today's CTO Royalties First Quarter twenty twenty five Earnings Call. My name is Ada, and I will be your operator today. All lines will be muted during the presentation of the call. There's an opportunity for questions and answers at the end. I would now like to pass the conference over to our host, Alisa Stevens, Vice President of Investor Relations. Please go ahead. Speaker1 Thanks, ...

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Sitio Royalties (STR) reported $16 ...

1Q25 Earnings Presentation May 7, 2025 Disclaimer FORWARD-LOOKING STATEMENTS This presentation relates to Sitio Royalties Corp. (the "Company", "STR" or "Sitio") and contains statements that may constitute "forward-looking statements" for purposes of federal securities laws. Forward-looking statements include, but are not limited to, statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions. The words "anticipate," "be ...

MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (the “Company” or “Osisko”) (OR: TSX & NYSE) is pleased to announce that the Board of Directors has approved a second quarter 2025 dividend of US$0.055 per common share, a 20% increase over the previous quarterly dividend, based on the foreign exchange rate (C$/US$) on the declaration date of the first quarter dividend. The dividend will be paid on July 15, 2025 to shareholders of record as of the close of business on June 30, 2025. This d ...

Black Stone Minerals (BSM) Q1 2025 Earnings Call May 06, 2025 10:00 AM ET Speaker0 Thank you for standing by. My name is Demi, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blackstone Minerals First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Mark Moe, Director ...

CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) and Rife Resources Management Ltd. (Rife) have mutually agreed to terminate the management agreement and associated services that Rife has historically provided Freehold. Effective May 1, 2025, Freehold will have a fully dedicated executive team and employee base and will no longer use the shared or advisory services of Rife to conduct its business. Freehold will not pay any termination fees or f ...

Core Insights - XOMA Royalty Corporation will have its Chief Investment Officer, Brad Sitko, presenting at the Jones Healthcare and Technology Innovation Conference on April 9, 2025 [1] - The presentation will be accessible online, and a replay will be available for 90 days post-event [2] Company Overview - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, assisting biotech companies in enhancing human health [3] - The company acquires future economic rights associated with therapeutic candidates that are licensed to pharmaceutical or biotechnology firms, providing sellers with non-dilutive, non-recourse funding [3] - XOMA has a growing portfolio of assets, defined as the rights to receive potential future economics linked to the advancement of therapeutic candidates [3]